Medicus Pharma Ltd. Common Stock (MDCX) Stock Forecast & Price Target
Medicus Pharma Ltd. Common Stock · OTCBB
$0.26+0.01 (+2.76%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Medicus Pharma Ltd. Common Stock, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $9.00 to $9.00, so the covering firms are broadly aligned. The average target of $9.00 sits 3308% above the current $0.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Medicus Pharma Ltd. Common Stock.
As of Aug, 1 of 1 firms rate MDCX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDCX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.15 – $-0.04 · 3 analysts · -87% YoY
Next period, 3 analysts expect Medicus Pharma Ltd. Common Stock to earn $-0.11 a share (range $-0.15 – $-0.04), versus $-0.83 a year earlier. Full-year consensus is $-0.54, growing to $-0.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Medicus Pharma Ltd. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDCX.
#1
Jason Kolbert
D. Boral Capital · Rank #407
Buy
$9.00+3307.8% to target
Overall win rate
22%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Buy
$20.00+7472.9% to target
Overall win rate
33%
+ Follow
#3
KR
Kumaraguru Raja
Brookline Capital Markets
Buy
$20.00+7472.9% to target
Coverage
—
+ Follow
MDCX stock forecast FAQ
What is MDCX's average 12-month price target?+
The 1 analysts with a live target average $9.00 for Medicus Pharma Ltd. Common Stock over the next 12 months, ranging from a $9.00 high to a $9.00 low.
Is MDCX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover MDCX?+
1 analysts have an active rating on Medicus Pharma Ltd. Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering MDCX?+
Among analysts who currently cover MDCX, Jason Kolbert of D. Boral Capital has the strongest overall Quantellect track record (Rank #407). Their current call is Buy with a $9.00 target.
What is Medicus Pharma Ltd. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.15 – $-0.04) across 3 analysts. Full-year EPS is projected at $-0.54, rising to $-0.38 the following year.
How much revenue is Medicus Pharma Ltd. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading MDCX lately?+
As of Aug, 1 of 1 firms rate MDCX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDCX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
